Table 2A.
Features of the hospital course for patients with COVID-19.
| Variable | COVID-19 positive | |||||
|---|---|---|---|---|---|---|
| Mild or no symptoms2 N = 38 | Severe acute symptoms3 N = 33 |
MIS-C4 N = 31 |
p-Value | Multiple comp* | ||
| Hospital course | ||||||
| Total inpatient days median (IQR) | 1.6 (0.7–7.2) | 8.6 (1.8–35.1) | 10.1 (7.5–13.3) | <0.001 | 2 < 3 & 4 | |
| Body weight for height (or length if <2 years of age), median (IQR) | ||||||
| Body mass index (BMI), Kg/m2 | 18 (15–23) N = 24 |
25 (17–36) N = 23 |
19 (17–21) N = 20 |
0.077 | All equal | |
| BMI percentile, %ile | 63 (9–87) | 94 (50–99) | 90 (66–98) | 0.114 | All equal | |
| N ≥ 95th <99th %ile | 2 (8%) | 4 (18%) | 3 (15%) | 0.609 | All equal | |
| N ≥ 99th %ile | 4 (17%) | 7 (32%) | 4 (20%) | 0.499 | All equal | |
| N ≤ 1st %ile | 6 (25%) | 3 (14%) | 1 (5%) | 0.217 | All equal | |
| Diagnostic codes during hospitalization, no. (%) | ||||||
| Pulmonary & upper respiratory | 2 (5%) | 24 (72%) | 21 (68%) | <0.001 | 2 < 3 & 4 | |
| Cardiac/cardiometabolic | 4 (11%) | 14 (42%) | 21 (68%) | <0.001 | 2 < 3 & 4 | |
| Endocrine | 5 (13%) | 8 (24%) | 2 (6%) | 0.143 | All equal | |
| GI/Hepatic | 8 (21%) | 8 (24%) | 16 (52%) | 0.014 | 2 < 4 | |
| Renal | 4 (11%) | 10 (30%) | 10 (32%) | 0.055 | All equal | |
| Immunosuppression | 1 (3%) | 6 (18%) | 25 (81%) | <0.001 | 2 & 3 < 4 | |
| Hematologic/Thrombotic | 3 (8%) | 10 (30%) | 14 (45%) | 0.001 | 2 < 4 | |
| Psychiatric | 8 (21%) | 9 (27%) | 4 (13%) | 0.378 | All equal | |
| CNS/seizures | 8 (21%) | 12 (36%) | 5 (16%) | 0.140 | All equal | |
| Pain | 21 (55%) | 23 (70%) | 28 (90%) | 0.006 | 2 < 4 | |
| Medications, no. (%) | ||||||
| Immunoglobulin | 0 (0%) | 4 (12%) | 26 (84%) | <0.001 | 2 & 3 < 4 | |
| Antiviral | 1 (3%) | 10 (30%) | 2 (6%) | 0.001 | 2 < 3 | |
| Corticosteroids/immunosuppression | 4 (11%) | 18 (55%) | 26 (84%) | <0.001 | 2 < 3 < 4 | |
| Antithrombotic | 5 (13%) | 22 (67%) | 25 (81%) | <0.001 | 2 < 3 & 4 | |
| Analgesic | 23 (61%) | 27 (82%) | 26 (84%) | 0.044 | All equal | |
| Antiseizure | 6 (16%) | 18 (55%) | 15 (48%) | 0.001 | 2 < 3 & 4 | |
| Glucoregulatory | 4 (11%) | 8 (24%) | 1 (3%) | 0.045 | All equal | |
| Psychotropic | 12 (32%) | 18 (55%) | 18 (58%) | 0.052 | All equal | |
| Level of respiratory support, no. (%) | ||||||
| Room air | 35 (92%) | 13 (39%) | 7 (23%) | <0.001 | 2 ≠ 3 & 4 | |
| Nasal canula | 2 (5%) | 5 (15%) | 8 (26%) | |||
| BiPAP or CPAP | 0 | 5 (15%) | 8 (26%) | |||
| Ventilator | 1 (3%) | 10 (30%) | 8 (26%) | |||
CNS, central nervous system; BiPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; IQR, interquartile range; kg/m2, kilograms per meter2; MIS-C, multisystem inflammatory syndrome of children; no., number.
*
Multiple comparisons; Bonferroni adjusted for three comparisons, significant p-value < 0.0167.